HER-2/neu in Breast Cancer: A Possible Means of Therapy?
HER-2/neu (synonyms are erbB-2, c-erbB-2) is a proto-oncogene from the erbB family located on chromosome 17q21 (Smith et al. 1993). This oncogene encodes a 185-kDa transmembrane glycoprotein with an extracellular region which is structurally similar to that of epidermal growth factor receptor and intracellular tyrosine kinase activity (Lupu et al. 1992; Harris et al. 1992). While the extracellular domain has ligand-binding activity (Staebler et al. 1994), the direct natural ligand of HER-2/neu is still unknown (Peles and Yarden 1993).
KeywordsBreast Cancer Breast Cancer Cell Peripheral Blood Mononuclear Cell Hormone Receptor Status Polymerase Chain Reac
Unable to display preview. Download preview PDF.
- Frank H, Valone FH, Kaufman PA, Guyre PM, Lewis LD, Memoli V, Deo Y, Graziano R, Fisher JL, Meyer L, Mrozek-Orlowski M, Wardwell K, Guyre V, Morley TL, Arvizu C, Fanger MW (1995) Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the protooncogene HER-2/neu. J Clin Oncol 13:2281–2292Google Scholar
- Paik S, Hazan R, Fisher ER, Sass RE, Fisher B, Redmond C, Schlessinger J, Lippman ME, King CR (1990) Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol 8:103–112PubMedGoogle Scholar
- Schonborn I, Zschiesche W, Spitzer E, Minguillon C, Mohner M, Ebeling K, Grosse R (1994) c-erbB-2 overexpression in primary breast cancer: independent prognostic factor in patients at high risk. Breast Cancer Res Treat 29:287–295Google Scholar
- Wiltschke C, Krainer M, Budinsky A, Berger A, Miiller C, Zeillinger R, Speiser P, Kubista E, Eibl M, Zielinski CC (1995) Reduced mitogenic stimulation of peripheral blood mononuclear cells as a prognostic parameter for the course of breast cancer: a prospective longitudinal study. Br J Cancer 71:1292–1296PubMedCrossRefGoogle Scholar